110 related articles for article (PubMed ID: 31160072)
21. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
[TBL] [Abstract][Full Text] [Related]
22. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.
Suidan RS; Zhou Q; Iasonos A; O'Cearbhaill RE; Chi DS; Long Roche KC; Tanner EJ; Denesopolis J; Barakat RR; Zivanovic O
Int J Gynecol Cancer; 2015 May; 25(4):599-606. PubMed ID: 25664437
[TBL] [Abstract][Full Text] [Related]
24. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
[TBL] [Abstract][Full Text] [Related]
25. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
van Baal JOAM; Van de Vijver KK; Algera MD; van der Aa MA; Sonke GS; van Driel WJ; Kenter GG; Amant FC; Lok CAR
Gynecol Oncol; 2019 Jun; 153(3):562-567. PubMed ID: 30948193
[TBL] [Abstract][Full Text] [Related]
26. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
28. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
29. Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registry data.
Adambekov S; Lopa S; Edwards RP; Lemon L; Wang S; Taylor SE; Orr B; Linkov F
Cancer Med; 2020 Oct; 9(20):7388-7397. PubMed ID: 32813321
[TBL] [Abstract][Full Text] [Related]
30. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
31. Study of efficacy and safety of modified adjuvant intraperitoneal chemotherapy regimen in carcinoma ovary.
Dash P; Goel V; Talwar V; Doval DC; Raina S; Goyal P; Upadhyay A; Patnaik N
Indian J Cancer; 2016; 53(4):607-611. PubMed ID: 28485363
[TBL] [Abstract][Full Text] [Related]
32. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
[TBL] [Abstract][Full Text] [Related]
33. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival.
Oei AL; Verheijen RH; Seiden MV; Benigno BB; Lopes A; Soper JT; Epenetos AA; Massuger LF
Int J Cancer; 2007 Jun; 120(12):2710-4. PubMed ID: 17354223
[TBL] [Abstract][Full Text] [Related]
34. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.
Aletti GD; Podratz KC; Cliby WA; Gostout BS
Gynecol Oncol; 2009 Jan; 112(1):22-7. PubMed ID: 18947860
[TBL] [Abstract][Full Text] [Related]
35. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up.
Zivanovic O; Barakat RR; Sabbatini PJ; Brown CL; Konner JA; Aghajanian CA; Abu-Rustum NR; Levine DA
Cancer; 2008 Jun; 112(12):2690-7. PubMed ID: 18428210
[TBL] [Abstract][Full Text] [Related]
37. Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
Le T; Latifah H; Jolicoeur L; Weberpals J; Faught W; Hopkins L; Fung MF
Gynecol Oncol; 2011 Jun; 121(3):451-4. PubMed ID: 21402403
[TBL] [Abstract][Full Text] [Related]
38. Intraperitoneal treatment for advanced ovarian cancer, the Dutch experience. What did we learn?
Rietveld MJA; van der Velden J; Westermann AM; van Driel WJ; Sonke GS; Witteveen PO; Ploos van Amstel FK; Massuger LFAG; Ottevanger PB
Neth J Med; 2020 Dec; 78(6):349-356. PubMed ID: 33380532
[TBL] [Abstract][Full Text] [Related]
39. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
[TBL] [Abstract][Full Text] [Related]
40. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
Varia MA; Stehman FB; Bundy BN; Benda JA; Clarke-Pearson DL; Alvarez RD; Long HJ;
J Clin Oncol; 2003 Aug; 21(15):2849-55. PubMed ID: 12885800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
